Risk of Rebleeding in Patients Suffering From Ruptured Brain Arteriovenous Malformations Undergoing Subacute Treatment: A Single-Center Series and Systematic Review of the Literature

2020 ◽  
Vol 134 ◽  
pp. e610-e615
Author(s):  
Patrick Schuss ◽  
Alexis Hadjiathanasiou ◽  
Inja Ilic ◽  
Simon Brandecker ◽  
Ági Güresir ◽  
...  
Neurosurgery ◽  
2019 ◽  
Vol 85 (5) ◽  
pp. E806-E814 ◽  
Author(s):  
Christopher L Davidoff ◽  
Anna Lo Presti ◽  
Jeffrey M Rogers ◽  
Mary Simons ◽  
Nazih N A Assaad ◽  
...  

Abstract BACKGROUND Recommendations on the management of brain arteriovenous malformations (bAVM) with respect to pregnancy are based upon conflicting literature. OBJECTIVE To systematically review the reported risk and annualized rate of first intracranial hemorrhage (ICH) from bAVM during pregnancy and puerperium. METHODS MEDLINE, EMBASE, and Scopus databases were searched for relevant articles in English published before April 2018. Studies providing a quantitative risk of ICH in bAVM during pregnancy were eligible. RESULTS From 7 initially eligible studies, 3 studies met the criteria for providing quantitative risk of first ICH bAVM during pregnancy. Data from 47 bAVM ICH during pregnancy across 4 cohorts were extracted for analysis. Due to differences in methodology and definitions of exposure period, it was not appropriate to combine the cases. The annualized risk of first ICH during pregnancy for these 4 cohorts was 3.0% (95% confidence interval [CI]: 1.7-5.2%); 3.5% (95% CI: 2.4-4.5%); 8.6% (95% CI: 1.8-25%); and 30% (95% CI: 18-49%). Only the last result from the last cohort could be considered significantly increased in comparison with the nonpregnant period (relative rate 6.8, 95% CI: 3.6-13). The limited number of eligible studies and variability in results highlighted the need for enhanced rigor of future research. CONCLUSION There is no conclusive evidence of an increased risk of first hemorrhage during pregnancy from bAVM. Because advice to women with bAVM may influence the management of pregnancy or bAVM with significant consequences, we believe that a retrospective multicenter, case crossover study is urgently required.


2007 ◽  
Vol 78 (11) ◽  
pp. 1213-1217 ◽  
Author(s):  
J van Beijnum ◽  
H B van der Worp ◽  
H M Schippers ◽  
O van Nieuwenhuizen ◽  
L J Kappelle ◽  
...  

2017 ◽  
Vol 4 (4) ◽  
Author(s):  
Ayesha A Appa ◽  
Rupali Jain ◽  
Robert M Rakita ◽  
Shahin Hakimian ◽  
Paul S Pottinger

Abstract Neurotoxicity due to cefepime has not been well characterized. We performed a systematic review of the literature and included 5 additional cases from our center. Of the 198 cases found, the mean age was 67 years and 87% of patients had renal dysfunction. The most common clinical features were diminished level of consciousness (80%), disorientation/agitation (47%), and myoclonus (40%). It is worth noting that nonconvulsive status epilepticus was relatively common with 31% of cases, whereas only 11% had convulsive seizures. Single-center estimate of incidence was 1 in 480 courses of cefepime. Cefepime neurotoxicity should be considered in older patients with renal dysfunction and new onset encephalopathy, especially if concurrent myoclonus is present. More work is needed to prospectively assess incidence and outcomes related to cefepime neurotoxicity.


Sign in / Sign up

Export Citation Format

Share Document